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Background/aim: The purpose of this study was to investigate the antiarthritic potentials of the inhibition of Src kinase in vivo and in
vitro settings.
Materials and methods: Arthritis was induced by intradermal injection of chicken type II collagen combined with incomplete Freund’s
adjuvant (collagen induced arthritis [CIA] model) in Wistar albino rats. One day after the onset of arthritis, dasatinib, a potent Src
kinase inhibitor, (5 mg/kg/day) was given via oral gavage. Tissue Src, Fyn, MAPK and STAT mRNA expressions were determined by
real-time polymerase chain reaction. On the other hand, fibroblast like synoviocytes (FLSs) were harvested patients with rheumatoid
arthritis (RA) undergoing surgical knee joint replacement. FLSs were stimulated with cytokines and dasatinib was added in different
concentrations. MMP –1, –3, and –13 levels in FLSs culture were determined by ELISA.
Results: The tissue mRNA expressions of Src, Fyn, MAPK and STATs were increased in the arthritis CIA group compared to the control
group. Their mRNA expressions in the CIA + dasatinib group were decreased and similar in the control group. In in vitro setting, MMP
–1, –3, and –13 expressions from FLSs induced by IL-1β and TNF-α were increased, while dasatinib suppressed their productions from
FLSs.
Conclusion: The present study shows that the inhibition of Src kinase has antiarthritic potentials in both in vivo and in vitro settings.
Src kinase inhibition may be candidate to further research in human RA.
Key words: Rheumatoid arthritis, collagen induced arthritis, src kinase, matrix metalloproteinase

1. Introduction
Rheumatoid arthritis (RA) is an inflammatory joint
disorder [1–4]. Its pathogenesis is not fully known, yet.
This disabling disease leads to chronic polyarthritis and
joint deformities. Thus, it leads to a significant health
and socioeconomic burden [1–4]. Although there is
magnificent advances about the treatment of RA, disease
modifying antirheumatic drugs (DMARDs) cannot
prevent deformities and lead to clinical remission in all RA
patients, as well as, several side effects of DMARDs can
restrict the prescribe in some patients. Due to requirement

for new therapeutic agents, biologic DMARDs such
as tumor necrosis factor (TNF)-α inhibitors (TNFi),
rituximab, abatacept, and tociluzumab are developed.
Widening therapeutic options lead to reach radiologic and
clinical remission in more patients. On the other hand,
30% of patients are achieved no responses, and some
patients stop treatment due to adverse effects or secondary
inadequate response. Thus, there is a requirement for the
treatment of RA, yet.
Src family kinases (SFKs) regulate cellular metabolism,
survival, and proliferation. They act roles on the
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production of inflammatory cytokines/mediators [5,6].
SFKs, nonreceptor tyrosine kinases, include 9 structurally
related molecules exhibiting similar functions. Src and Fyn
belong to the SFKs. Both Src and Fyn exhibit ubiquitous
expression, therefore they are involved in a variety of signal
transduction pathways [7,8]. Thus, they play important
roles in immune cell development, proliferation, adhesion,
migration, chemotaxis, phagoscytosis, and survival.
Moreover, Src and Fyn signaling result in the activation of
signal transducers and activators of transcription (STAT)
and mitogen-activated protein kinase (MAPK) which play
pivotal roles in the pathogenesis of RA [1].
It has been reported that activated Src kinase is
expressed by synovial cells and synovial macrophages in
patients with RA [9]. Moreover, the depletion of Src kinase
and SFKs has been shown to ameliorate the arthritis in rats
[10]. Therefore, the purpose of this study was to investigate
the antiarthritic potentials of the inhibition of Src kinase
in vivo and in vitro settings.
2. Materials and methods
2.1. Animals
This study included 30 Wistar-albino female rats of 8–10
weeks old with weights varying between 220 and 260
g. Animals were housed in separate cages at a relative
humidity rate of 70%–30% and a temperature rate of 24
± 3 °C. A 12 h day: 12 h night cycle was followed. All rats
were given ad libitum access to water. The sample size
calculation is based on a previous study [11]. The study
protocol was approved by the local animal ethic board
(12.06.2013/78).
2.2. Experimental design
In this study, collagen induced arthritis (CIA) model
was used to induce arthritis. The rats were divided into
3 groups: control group, arthritis (CIA) group, and
dasatinib, which is a potent Src kinase inhibitor, treatment
group. Each group consisted of 10 rats. Type 2 collagen
(Sigma Aldrich Company, USA) was diluted with acetic
acid (0.1 M concentration). Complete Freund’s adjuvant
(Difco Laboratories, USA) was added to this solution. The
solution was intradermally to the tail (100 µg) and each
paws (total 200 µg to each animal). On the 7th day of the
experiment, 100 µg booster doses were injected to each rat.
Arthritis developing after collagen injection was scored
separately for each rat. The severity of arthritis was scored
according to the method previously described; score 0 was
described as no erythema or edema, score 1 was described
as mild erythema and edema in the foot or ankle, score 2
was described as mild erythema and edema in the paw,
score 3 was described as moderate erythema and edema
in the paw 3, score 4 was described as marked edema and
anchylosis, and restricted movement in the paw [11,12].
After the onset of arthritis, dasatinib (5 mg/kg/day) was

started to give via oral gavage, until the rats were sacrificed
on day 29 [13].
2.3. Sample acquisition
After sacrificed, back paws were cut under the knee joint
for histopathological evaluation and blood samples were
taken for analyses. Joint samples were divided into two
groups for the real-time polymerase chain reaction (PCR)
analyses and histopathologic examinations [12,14]. The
Hematoxylin-Eosin (H & E) stained lames were examined
blindly by a pathologist for the histopathologic scoring of
arthritis [12,14].
2.4. Real-time PCR analysis
According to the manufacturer’s total RNA from paws
was extracted using Trizol reagent (Invitrogen, Carlsbad,
CA, USA). cDNA was obtained by reverse transcription
of total RNA samples with the cDNA Synthesis kit
(Invitrogen, Carlsbad, CA, USA). Real time PCR reactions
were performed in triplicate (heated to 50 °C for 2 min
followed by 1 cycle of denaturation at 94 °C for 10 min, 40
cycles of 94 °C for 15 s, and 60 °C for 60 s). Standard curves
were prepared for target genes and endogenous reference
(HPRT) in each sample. The ABI Prism 7500 Fast Real
Time PCR Instrument (Applied Biosystems, CA, USA) for
real-time PCR analysis was used in this study with using
Tag Man Master Mix (Applied Biosystems, CA, USA).
All results are standardized according to GAPDH levels.
The samples were quantified for MAPK, Fyn, Src, and
STAT3 genes using the comparative Ct (ΔΔCt) protocol,
according to the Assays–on-Demand User’s Manual
(Applied Biosystems, CA, USA).
2.5. The inhibition of Src kinase in fibroblast-like
synoviocytes cell culture
Human FLS harvested from patients with RA were
purchased from Sigma Aldrich (St. Louis, Missouri,
USA). In this study, the FLS-RA were pre-exposed to proinflammatory cytokine those are IL-1β and TNF-α and
initiated inflammation in chondrocytes [15]. The FLS-RA
cultures were incubated for overnight with serum starved
medium (0.5% FCS). Serum-starved the FLS-RA were pre
-stimulated with 5 ng/mL IL-1β and 10 ng/mL TNF-α for
24 h Sigma Aldrich (St. Louis, Missouri, USA) before being
treated with dasatinib (Bristol-Myers Squibb, Istanbul,
Turkey). After overnight, various concentrations (1 to 20
μM) of dasatinib were administered to induce FLS - RA
cell cultures and incubated for 24 h. To investigate effect
of dasatinib in inflamed cells was studied MTS assays
(Cambridge, UK) and ELISA assays. MMP –1, –3, and
–13 levels in FLS-RA culture were determined by ELISA
(Cambridge, UK).
2.6. Statistical analysis
The sample size of this study was eight per group and it
was calculated based on an alpha error of 0.05 and a power
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of 80% and of 90% (GPower3.1). Data were analyzed using
the Statistical Product and Service Solutions (SPSS, v: 22.0)
software for windows. All data were presented as mean ±
standard deviation. Kruskal–Wallis one-way analysis of
variance and Mann–Whitney U test for dual-comparisons
were used for statistical analysis. For categorical data
analysis, spearman Chi-square test was used. Differences
in arthritis severity scoring were analyzed by the Wilcoxon
rank-sum test. P values less than 0.05 were considered
significant.
3. Results
3.1. Clinical arthritis scoring
Joint swelling and erythema were observed at 12 to 13
days after the first injection of collagen in rats from the
CIA group and CIA + dasatinib groups. The mean arthritis
scores were higher in the CIA group and CIA + dasatinib
groups compared to the control group (Figure 1). Dasatinib
ameliorated arthritis. The mean 29th day arthritis scores
were decreased in the CIA + dasatinib group compared to
the own mean 14th day arthritis score (Wilcoxon Rank p
< 0.001). Moreover, the 29th day arthritis score of CIA +
dasatinib group was decreased compared to the mean 29th
day arthritis score of CIA group (p < 0.001) (Figure 1).
3.2. Pathological examinations
The extensive perisynovial inflammation and marked
cartilage - bone destruction in the CIA group rats were
demonstrated by histopathological analysis (Figure 2A and
Figure 2B). On the other hand, dasatinib ameliorated the
perisynovial inflammation and cartilage-bone destruction
in the paws (Figure 2C).
3.3. mRNA expressions from joint tissues
The tissue mRNA expressions of Src (Figure 3A), Fyn
(Figure 3B), MAPK (Figure 3C) and STAT3 (Figure
3D) (for all, p < 0.001) were increased in the CIA group
compared to the control group. However, dasatinib
treatment suppressed the tissue mRNA expressions of Src,
Fyn, MAPK (p = 0.009), and STAT3 (for all, p < 0.001).
Their mRNA expressions in CIA + dasatinib group were
similar in the control group (p > 0.05).
3.4. The productions of MMPs from FLS-RA
In in vitro setting, IL-1β, and TNF-α induced FLS-RA.
The applications of IL-1β and TNF - α on FLS-RA culture
increased the production of MMP –1, –3, and –13 (p
< 0.05). On the other hand, dasatinib suppressed the
productions of MMP–1 ((Figure 4A), MMP–3 (Figure 4B),
and MMP–13 (Figure 4C) from FLS-RA induced by IL-1β
and TNF-α (p < 0.05).
4. Discussion
In the present study, the effects of Src and Fyn kinase
inhibition by dasatinib were researched on CIA and
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cell culture of FLS. The mRNA expressions of Src and
Fyn kinases were increased in the rats with clinically
and histopathologically evident arthritis. When the rats
with arthritis were treated with dasatinib, clinical and
histopathological findings of arthritis are ameliorated,
as well as, the mRNA expressions of Src and Fyn kinases
were decreased, in our study. Moreover, in in vitro setting,
the induction of FLS by IL-1 and TNF-α increased the
production of MMPs. When dasatinib was applied to
IL-1 and TNF-α induced FLS, the levels of MMPs were
decreased, in our study.
Src-family kinases affect various cellular signaling
pathways, those regulate the motility, survival,
proliferation, adhesion, and invasion of cells [6–8]. It has
been reported that activated Src is expressed by synovial
cells and synovial macrophages in patients with RA [9].
Moreover, the depletion of Src and SFKs has been shown
to ameliorate the arthritis in rats [10]. In the present study,
it was shown that Src and Fyn mRNA expressions are
increased in the rats with arthritis, and dasatinib a SFK
inhibitor ameliorates arthritis and depletes the expressions
of Src and Fyn in CIA model. Moreover, dasatinib decreases
the production of MMP from FLS in in vitro setting. These
results may suggest that SFKs have prominent roles on the
pathogenesis of RA.
The p38 MAPK pathway in RA plays pivotal roles
[16]. Activation of p38 MAPK triggers the production of
several pro-inflammatory cytokines such as TNF, IL-1 and
IL-6 in synovium and the inhibition of p38 MAPK with
a synthetic inhibitor has decreased inflammation [17].
Moreover, recent accumulated evidences demonstrate that
the p38 MAPK pathway has a central role in emergence of
cartilage and bone destruction in RA through synthesis of
MMPs, formation of osteoclasts, and angiogenesis [16,17].
On the other hand, several reports show that SFKs are
associated with the p38 MAPK pathway [18–20]. Summy et
al. [18] have showed the p38 MAPK activation is regulated
by Src kinase. Another study has demonstrated that the
inhibition of Src activation with a SFK inhibitor reduced
p38 MAPK activation [20]. And they reported that Src
kinase is essential for the activation of p38 MAPK in spinal
microglia cell culture [20]. In the present study, it has been
observed that MAPK mRNA expression is increased in
CIA, while dasatinib ameliorates arthritis and depletes the
mRNA expression of MAPK in this experimental arthritis
model. These results suggest that the relationship between
SFK and MAPK has a role in inflammatory arthritis.
STATs are a family of cytoplasmic transcription factors,
they are activated when critical tyrosine residues become
phosphorylated by tyrosine kinases. When the tyrosine
residues of STAT proteins become phosphorylated, STATs
translocate to the nucleus. And thus, they bind to cognate
sequences contained within gene promoters and regulate
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Figure 1. The scores of arthritis in the study groups *The mean arthritis scores were
higher in the CIA group and CIA + dasatinib groups compared to the control group
(p < 0.05). **The 29th day arthritis scores were decreased in the CIA + dasatinib group
compared to the own 13th day score (p < 0.05). ***29th day arthritis score of CIA +
dasatinib group was decreased compared to the 29th day score of CIA group (p < 0.05).

Figure 2. Histopathological sections of joints in study groups (H&E X400). Histopathological appearance of the joint was normal in the
control group (A). Obvious perisynovial inflammation (arrow) and destruction of cartilage-bone (star) were observed in the arthritis
CIA group (B). Perisynovial inflammation and synovial hyperplasia were decreased in the CIA + dasatinib group (C).

gene expression [21]. Numerous pro-inflammatory
cytokines are increased in RA and they activate STAT
signaling pathway. Activation of STAT is one of the leading
actors in the pathogenesis of RA [22]. In RA, the increased
activity of STAT3 in inflammatory cells and synovial
fibroblasts has been documented and the STAT3 is
associated with the development of the disease [22]. Oike
et al. [23] have shown that STAT3 inhibitors ameliorate
arthritis in CIA model. On the other hand, Schreiner et
al. [24] have demonstrated that Src kinases activate STAT3
in in vitro setting. In our study, dasatinib decreased the
mRNA expressions of Src kinase and STAT3 from joint
tissues. This result supports that the effect of Src kinase
on inflammatory arthritis may also be related with their
actions on STATs.

Kovacs et al. [25] have documented that knockout
mice for Src kinases are protected from inflammatory cell
infiltrations in an experimental arthritis model. It is due
to defective productions of cytokines and chemokines
by inflammatory cells infiltrating inflame joints [25].
Dasatinib, a Src kinase inhibitor, is shown to inhibit the
production of TNF-α, IL-6, and IL-8 from macrophages,
monocytes and RA-synovial fibroblasts as well as dasatinib
affects the activations of these cells [26]. In our study,
dasatinib decreased the productions of MMPs from RAFLS. Kramer et al. [27] have documented that dasatinib
reduces the production of MMM-9 from 3 different
cell lines originating from patient with squamous cell
carcinoma. In RA, pro-inflammatory cytokines affect FLSs
and macrophages to release MMPs those are responsible to
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Figure 3. The joint tissue mRNA expressions in the study groups. The joint tissue mRNA expressions of Src (A),
Fyn (B), MAPK (C), and STAT3 (D) were higher in the arthritis CIA group compared to the control group. Their
expressions were decreased in the dasatinib treated group compared to the CIA group. MAPK; mitogen-activated
protein kinase, STAT; signal transducers, and activators of transcription *p < 0.05 when compared with control and
CIA + dasatinib group.

joint destructions [28]. In our study, it has been observed
that dasatinib decreased the productions of MMPs from
RA-FLSs.
There are some limitations in the present study. We
assessed the expressions of Src, Fyn, MAPK, and STAT
mRNA. But, they do not indicate their protein levels
and activities. Moreover, it would have been better if
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erythrocyte sedimentation rate, C-reactive protein level,
and complete blood count were also evaluated.
Dasatinib is a second generation tyrosine-kinase
inhibitor to treat chronic myeloid leukemia. The present
study shows that dasatinib has antiarthritic potentials in
both in vivo and in vitro settings. It may be candidate to
further research in human RA.

YALÇIN KEHRİBAR et al. / Turk J Med Sci

Figure 4. The productions of matrix metalloproteinases from synovial fibroblasts IL-1β and TNF-α applications increased the
productions of MMP-1 (A), MMP-3 (B), and MMP-13 (C). Various concentrations of dasatinib decreased the productions of MMP-1
(A), MMP-3 (B), and MMP-13 (C) from RA-FLSs induced by IL-1β and TNF-α. MMP; matrix metalloproteinase, IL; interleukin, TNF;
tumor necrosis factor *p < 0.05 when compared with all other study groups.

Acknowledgment
The authors would like to thank Enago (www.enago.com)
for English language review.
Author contributions
All authors make substantial contributions to conception

and design, and/or acquisition of data, and/or analysis and
interpretation of data.
Funding
This study supported by Fırat Üniversitesi Bilimsel
Araştırma Projeleri (TF.13.53).

2147

YALÇIN KEHRİBAR et al. / Turk J Med Sci
References
1.

Bellucci E, Terenzi R, La Paglia GM, Gentileschi S, Tripoli A
et al. One year in review 2016: pathogenesis of rheumatoid
arthritis. Clinical and Experimental Rheumatology 2016; 34
(5): 793-801.

2.

Kim K, Bang SY, Lee HS, Bae SC. Update on the genetic
architecture of rheumatoid arthritis. Nature Reviews
Rheumatology 2017; 13 (1): 13-24. doi: 10.1038/
nrrheum.2016.176

3.

Udalova IA, Mantovani A, Feldmann M. Macrophage
heterogeneity in the context of rheumatoid arthritis. Nature
Reviews Rheumatology 2016; 12 (8): 472-485. doi: 10.1038/
nrrheum.2016.91

4.

Calabrò A, Caterino AL, Elefante E, Valentini V, Vitale A
et al. One year in review 2016: novelties in the treatment of
rheumatoid arthritis. Clinical and Experimental Rheumatology
2016; 34 (3): 357-372.

5.

Chen R, Chen B. The role of dasatinib in the management of
chronic myeloid leukemia. Drug Design Development and
Therapy 2015; 9 (9): 773-779. doi: 10.2147/DDDT.S80207

6.

Byeon SE, Yi YS, Oh J, Yoo BC, Hong S et al. The role of Src kinase
in macrophage-mediated inflammatory responses. Mediators
of Inflammation 2012; 2012:512926. doi: 10.1155/2012/512926

7.

Liu ST, Pham H, Pandol SJ, Ptasznik A. Src as the link between
inflammation and cancer. Frontiers in Physiology 2014; 4 (4):
416. doi: 10.3389/fphys.2013.00416

8.

Christopher L, Scott K. The Src family of protein tyrosine
kinases: a new and promising target for colorectal cancer
therapy. Clinical Colorectal Cancer 2010; 9 (2): 89-94. doi:
10.3816/CCC.2010.n.012

9.

Shahrara S, Castro-Rueda HP, Haines GK, Koch AE.
Differential expression of the FAK family kinases in rheumatoid
arthritis and osteoarthritis synovial tissues. Arthritis Research
& Therapy 2007; 9 (5): R112. doi: 10.1186/ar2318

10.

Takayanagi H, Juji T, Miyazaki T, Iizuka H, Takahashi T et
al. Suppression of arthritic bone destruction by adenovirusmediated csk gene transfer to synoviocytes and osteoclasts.
Journal of Clinical Investigation 1999; 104 (2): 137-146. doi:
10.1172/JCI6093

14.

Barsante MM, Roffê E, Yokoro CM, Tafuri WL, Souza DG et
al. Anti-inflammatory and analgesic effects of atorvastatin in
a rat model of adjuvant-induced arthritis. European Journal
of Pharmacology 2005; 516 (3): 282-289. doi: 10.1016/j.
ejphar.2005.05.005

15.

Huber LC, Künzler P, Boyce SH, Michel BA, Gay RE et al.
Effects of a novel tyrosine kinase inhibitor in rheumatoid
arthritis synovial fibroblasts. Annals of the Rheumatic Diseases
2008; 67: 389-394. doi: 10.1136/ard.2007.072330

16.

Paunovic V, Harnett MM. Mitogen-activated protein kinases
as therapeutic targets for rheumatoid arthritis. Drugs 2013; 73
(2): 101-115. doi: 10.1007/s40265-013-0014-6

17.

Kunisch E, Gandesiri M, Fuhrmann R, Roth A, Winter
R et al. Predominant activation of MAP kinases and prodestructive/pro-inflammatory features by TNF alpha in
early-passage synovial fibroblasts via TNF receptor-1: failure
of p38 inhibition to suppress matrix metalloproteinase-1 in
rheumatoid arthritis. Annals of the Rheumatic Diseases 2007;
66 (8): 1043-1051. doi: 10.1136/ard.2006.062521

18.

Summy JM, Trevino JG, Baker CH, Gallick GE. c-Src regulates
constitutive and EGF-mediated VEGF expression in pancreatic
tumor cells through activation of phosphatidyl inositol-3
kinase and p38 MAPK. Pancreas 2005; 31 (3): 263-274. doi:
10.1097/01.mpa.0000178280.50534.0c

19.

Yang CM, Lee IT, Lin CC, Wang CH, Cherng WJ et al. c-Srcdependent MAPKs/AP-1 activation is involved in TNF-αinduced matrix metalloproteinase-9 expression in rat heartderived H9c2 cells. Biochemical Pharmacology 2013; 85 (8):
1115-1123. doi: 10.1016/j.bcp.2013.01.013

20.

Tan YH, Li K, Chen XY, Cao Y, Light AR et al. Activation
of Src family kinases in spinal microglia contributes to
formalin-induced persistent pain state through p38 pathway.
The Journal of Pain 2012; 13 (10): 1008-1015. doi: 10.1016/j.
jpain.2012.07.010

21.

Haura EB. SRC and STAT pathways. Journal of Thoracic
Oncology 2006; 1 (5): 403-405.

22.

Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid
arthritis. The Journal of Rheumatology 2005; 32 (9): 16501653.

23.

Oike T, Sato Y, Kobayashi T, Miyamoto K, Nakamura S et al.
Stat3 as a potential therapeutic target for rheumatoid arthritis.
Scientific Reports 2017; 7 (1): 10965. doi: 10.1038/s41598-01711233-w

11.

Ozgen M, Koca SS, Karatas A, Dagli AF, Erman F et al. Lapatinib
ameliorates experimental arthritis in rats. Inflammation 2015;
38 (1): 252-259. doi: 10.1007/s10753-014-0028-6.12

12.

Trentham DE, Townes AS, Kang AH. Autoimmunity to type
II collagen an experimental model of arthritis. Journal of
Experimental Medicine 1977; 146 (3): 857-868. doi: 10.1084/
jem.146.3.857

24.

Schreiner SJ, Schiavone AP, Smithgall TE. Activation of STAT3
by the Src family kinase Hck requires a functional SH3 domain.
The Journal of Biological Chemistry 2002; 277 (47): 4568045687. doi: 10.1074/jbc.M204255200

13.

Vandyke K, Dewar AL, Diamond P, Fitter S, Schultz CG et
al. The tyrosine kinase inhibitor dasatinib dysregulates bone
remodeling through inhibition of osteoclasts in vivo. Journal
of Bone and Mineral Research 2010; 25 (8): 1759-1770. doi:
10.1002/jbmr.85

25.

Kovács M, Németh T, Jakus Z, Sitaru C, Simon E et al. The Src
family kinases Hck, Fgr, and Lyn are critical for the generation
of the in vivo inflammatory environment without a direct role
in leukocyte recruitment. Journal of Experimental Medicine
2014; 211 (10): 1993-2011. doi: 10.1084/jem.20132496

2148

YALÇIN KEHRİBAR et al. / Turk J Med Sci
26.

To WS, Aungier SR, Cartwright AJ, Ito K, Midwood KS. Potent
anti-inflammatory effects of the narrow spectrum kinase
inhibitor RV1088 on rheumatoid arthritis synovial membrane
cells. British Journal of Pharmacology 2015; 172 (15): 38053816. doi: 10.1111/bph.13170

27.

Kramer B, Schultz JD, Hock C, Sauter A, Stuck BA et al.
Effect of selective small molecule inhibitors on MMP-9 and
VEGFR-1 expression in p16-positive and -negative squamous
cell carcinoma. Oncology Letters 2017; 13 (5): 3269-3276. doi:
10.3892/ol.2017.5844

28.

Huang J, Xie B, Li Q, Xie X, Zhu S et al. Infliximab reduces
CD147, MMP-3, and MMP-9 expression in peripheral blood
monocytes in patients with active rheumatoid arthritis.
European Journal of Pharmacology 2013; 698 (1-3): 429-434.
doi: 10.1016/j.ejphar.2012.10.030

2149

